
Phase-3 study shows Trastuzumab Pamirtecan improves progression-free survival in HR+/HER2-low metastatic breast cancer.
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...





